$75M Series B for Multiply Labs: NantWorks Backs Robotic Drug Manufacturing Systems

Multiply Labs has secured $75 million in Series B financing to support its development of robotic automation for the pharmaceutical industry. According to reporting by Techmeme, the round was led by NantWorks, an entity associated with Patrick Soon-Shiong. The capital injection targets the expansion of equipment designed to streamline drug production processes for pharmaceutical manufacturers.

The risk

For business leaders in the life sciences sector, the primary consideration is operational continuity and supply chain resilience. The deployment of automated robotic systems aims to reduce manual handling errors and increase throughput in manufacturing environments. Relying on specialized automation vendors introduces dependency risks that must be managed through robust vendor evaluation and service level agreements.

Who is exposed

Drugmakers and pharmaceutical manufacturers represent the direct beneficiary group for this technology. Organizations currently scaling production capacity or seeking to modernize legacy manufacturing lines are the primary audience for Multiply Labs’ solutions. The funding indicates a strategic push to address bottlenecks in drug production that affect broader healthcare supply chains.

Cost and compliance

The $75 million funding amount reflects market confidence in the scalability of automated pharma solutions. While the source material does not detail specific compliance impacts, pharmaceutical manufacturing remains subject to strict regulatory oversight. Implementing new robotic systems requires alignment with existing quality control standards to ensure that automation enhances rather than complicates regulatory adherence.

What should you do?

Operations managers should evaluate current manufacturing bottlenecks to determine if robotic automation offers a viable solution. Procurement teams must assess the financial stability and technical roadmap of automation vendors before committing to long-term contracts. It is essential to define clear performance metrics for any new automated systems to ensure they deliver the promised operational efficiencies.

What to do and how to stay safe: Multiply Labs

• Review current manufacturing workflows to identify specific processes where robotic automation could reduce manual error rates.
• Assess the financial health and track record of potential automation vendors to mitigate supply chain dependency risks.
• Establish clear performance benchmarks and service level agreements before integrating new robotic systems into production lines.
• Ensure that any new automated equipment complies with existing pharmaceutical regulatory standards and quality control protocols.

Step-by-step guide: Mobile Security Architecture: 8 Practices for Device Integrity

General security guidance from the Vector Tribune newsroom. It is not confirmed advice from the organisations named in this story.

Frequently asked questions

Who led the latest funding round for Multiply Labs?

NantWorks, associated with Patrick Soon-Shiong, led the $75 million Series B round according to Techmeme.

What does Multiply Labs develop?

The company develops robotic systems and automation equipment specifically for pharmaceutical manufacturing processes.

How much funding did Multiply Labs raise?

Multiply Labs raised $75 million in its Series B financing round.